Albuvirtide

Drug Profile

Albuvirtide

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Frontier Biotechnologies
  • Class Antivirals; Maleimides; Peptides
  • Mechanism of Action HIV envelope protein gp41 inhibitors; HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration HIV infections

Most Recent Events

  • 25 Jul 2017 3BNC 117 antibody licensed to Frontier Biotechnologies for combination studies with albuvirtide worldwide for the prevention and treatment of HIV infections
  • 25 Jul 2017 Frontier Biotechnologies plans a clinical trial for HIV infections (Combination therapy) in 2018
  • 06 Jun 2016 Frontier Biotechnologies announces intention to submit NDA to China Food and Drug Administration in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top